Inhibrx 提交 ozekibart 用于常规软骨肉瘤的 BLA

Inhibrx 于 2026 年 4 月向 FDA 提交了 ozekibart 用于常规软骨肉瘤的 BLA。该公司还计划在 2026 年下半年与 FDA 会面，讨论 CRC 一线注册试验以及 CRC 四线和难治性尤文肉瘤的潜在加速审批途径。

关键事实

申报时间: 2026年4月21日 20:04
事件: 申请已提交
方向: 中性
公司: INBXInhibrx
资产: ozekibart
来源: SEC 8-K
可信度: 有来源

来源摘录

inhibrx-20260421 FALSE 0002007919 0002007919 2026-04-21 2026-04-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2026 INHIBRX BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-42031 99-0613523 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 11025 N. Torrey Pines Road , Suite 140 La Jolla , CA 92037 (Address of Principal Executive Offices and Zip Code) Registrant’s telephone number, including area code: ( 858 ) 795-4220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy th

SEC 8-K